5J7S

Crystal structure of SM1-71 bound to TAK1-TAB1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.368 Å
  • R-Value Free: 0.240 
  • R-Value Work: 0.228 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Structure-guided development of covalent TAK1 inhibitors.

Tan, L.Gurbani, D.Weisberg, E.L.Hunter, J.C.Li, L.Jones, D.S.Ficarro, S.B.Mowafy, S.Tam, C.P.Rao, S.Du, G.Griffin, J.D.Sorger, P.K.Marto, J.A.Westover, K.D.Gray, N.S.

(2017) Bioorg. Med. Chem. 25: 838-846

  • DOI: 10.1016/j.bmc.2016.11.035
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • TAK1 (transforming growth factor-β-activated kinase 1) is an essential intracellular mediator of cytokine and growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of ...

    TAK1 (transforming growth factor-β-activated kinase 1) is an essential intracellular mediator of cytokine and growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys174, a residue immediately adjacent to the 'DFG-motif' of the kinase activation loop. Co-crystal structures of TAK1 with candidate compounds enabled iterative rounds of structure-based design and biological testing to arrive at optimized compounds. Lead compounds such as 2 and 10 showed greater than 10-fold biochemical selectivity for TAK1 over the closely related kinases MEK1 and ERK1 which possess an equivalently positioned cysteine residue. These compounds are smaller, more easily synthesized, and exhibit a different spectrum of kinase selectivity relative to previously reported macrocyclic natural product TAK1 inhibitors such as 5Z-7-oxozeanol.


    Organizational Affiliation

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Mitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 chimera
A
314Homo sapiensMutation(s): 0 
Gene Names: TAB1 (MAP3K7IP1), MAP3K7 (TAK1)
EC: 2.7.11.25
Find proteins for Q15750 (Homo sapiens)
Go to Gene View: TAB1
Go to UniProtKB:  Q15750
Find proteins for O43318 (Homo sapiens)
Go to Gene View: MAP3K7
Go to UniProtKB:  O43318
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
6H3
Query on 6H3

Download SDF File 
Download CCD File 
A
N-{2-[(5-chloro-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propanamide
C24 H28 Cl N7 O
IIMJCIGRKJCCHT-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.368 Å
  • R-Value Free: 0.240 
  • R-Value Work: 0.228 
  • Space Group: I 2 2 2
Unit Cell:
Length (Å)Angle (°)
a = 58.234α = 90.00
b = 134.060β = 90.00
c = 146.814γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
PHENIXrefinement
SCALEPACKdata scaling
HKL-3000data reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Cancer Prevention and Research Institute of Texas (CPRIT)United StatesCPRIT R1207 and CPRIT RP140233

Revision History 

  • Version 1.0: 2017-02-15
    Type: Initial release
  • Version 1.1: 2017-09-27
    Type: Author supporting evidence
  • Version 1.2: 2020-01-08
    Type: Author supporting evidence